In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA-approved CRISPR-Cas9 gene editing treatment. The therapy—which involves removing blood stem ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

A little over a year ago, the FDA approved Casgevy, a cellular therapy, for the treatment of sickle cell disease and beta-thalassemia. Vertex and CRISPR Therapeutics haven't started recording ...

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can go ahead, after the FDA lifted a hold on a review. The companies had applied ...

Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

Why are CRISPR companies not OK ... and the approval of a non-opioid pain drug from Vertex Pharmaceuticals. Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized ...

Vertex and CRISPR Therapeutics haven't started recording ... the treatment process with over 50 patients. In December, the FDA approved Alyftrek, a new once-daily pill for patients with cystic ...